The discussions will include fertility, menopause and flexible working.
BSAVA has announced a programme of wellbeing presentations and discussions during BSAVA Congress 2023, covering hormonal health, self-compassion and learning to work with grief.
The immersive and interactive sessions have been created in collaboration with leading experts from both inside and outside the profession, including Vetlife, BVA and the BVLGBT+.
Menstrual issues, polycystic ovary syndrome, fertility and menopause will go under the spotlight in four separate discussions on hormonal health across all gender identities. There will also be sessions on support for gender transition, non-binary people and male ageing.
Other sessions will explore supporting self-compassion as an antidote to perfectionism, learning to work alongside grief, flexible working and developing 'human-savvy' teamwork.
BSAVA president Alison Speakman said: “This year has continued to provide increasing challenges both within the veterinary workforce and in the world at large. This has challenged our physical, mental, and financial wellbeing which are inextricably linked.
Therefore, we will be covering aspects of all three with a wide range of presenters included in these conversations, from both within and outwith the veterinary arena.
“Whether you wish to expand your knowledge to improve personal understanding and support of your own wellbeing, that of a colleague or friend, or to improve workplace practices and culture, there really is something for everyone to learn. Please come along to our safe and supportive space at Congress to improve the wellbeing of our veterinary profession.
“This year we are collaborating with BVCIS, BVEDS, BVLGBT+, Mind Matters Initiative (MMI), Vetlife, BVA, and other experts working in this space to be able to create the best wellbeing programme possible.”
For more information about the Wellbeing Programme, click here.
Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.
